Status:
RECRUITING
The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Conditions:
Carotid Artery Stenosis
Carotid Artery Stenosis Asymptomatic
Eligibility:
All Genders
60-80 years
Brief Summary
Stroke is the second leading cause of death and the third leading cause of disability worldwide. The cause is usually either a blockage or a severe narrowing of a cerebral artery. An important part of...
Eligibility Criteria
Inclusion
- Age 60- 80 years
- 0-100 % stenosis of the internal carotid artery
Exclusion
- Neurodegenerative diseases such as any form of dementia or Parkinson\'s disease
- Polyneuropathy
- Multiple sclerosis
- Stroke (ischaemic or haemorrhagic) within the last 12 months
- Transient ischaemic attack within the last 12 months
- Neurotrauma within the last 12 months
- Atrial fibrillation
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06211725
Start Date
January 1 2023
End Date
January 1 2025
Last Update
January 18 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany, 40225
2
Kliniken Maria Hilf GmbH
Mönchengladbach, North Rhine-Westphalia, Germany, 41063